-
Product Insights
Intestinal Cancer Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Intestinal Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Intestinal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Intestinal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Pediatric Cancer Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Pediatric Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Pediatric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Pediatric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Round Cell Liposarcoma Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Round Cell Liposarcoma Global Clinical Trials Review, H2, 2016" provides an overview of Round Cell Liposarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Round Cell Liposarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Pilocytic Astrocytoma Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Pilocytic Astrocytoma Global Clinical Trials Review, H2, 2016" provides an overview of Pilocytic Astrocytoma clinical trials scenario. This report provides top line data relating to the clinical trials on Pilocytic Astrocytoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Myxoid Liposarcoma Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Myxoid Liposarcoma Global Clinical Trials Review, H2, 2016" provides an overview of Myxoid Liposarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Myxoid Liposarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Liposarcoma Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Liposarcoma Global Clinical Trials Review, H2, 2016" provides an overview of Liposarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Liposarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Extrahepatic Bile Duct Cancer Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Extrahepatic Bile Duct Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Extrahepatic Bile Duct Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Extrahepatic Bile Duct Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players
GlobalData has released its pharma report, “Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – US Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – 5EU Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.